Supplementary Table 1. Trial registration – data set

Data category	Information
Primary registry and trial identifying number	NCT06163547
Date of registration in primary registry	11th December, 2023
Secondary identifying numbers	BASEC2023-00848, SNCTP000005765, RP04-16.
Primary sponsor	Fondation privée des HUG
Secondary sponsor(s)	None
Contact for public queries	Karl Schaller MD [karl.schaller@hcuge.ch]
Contact for scientific queries	Karl Schaller MD [karl.schaller@hcuge.ch]
Public title	Middle Meningeal Artery (MMA) Embolization for chronic Subdural Hematomas
Scientific title	Middle Meningeal Artery (MMA) Embolization for chronic Subdural Hematomas: Rationale and Design for the STOp Recurrence of MMA Bleeding (STORMM) Randomized-Control Trial
Countries of recruitment	Switzerland
Health condition(s) or problem(s) studied	Chronic Subdural Hematomas, recurrence
Intervention(s)	Arm 1 (conventional management/control): surgery without embolization (randomized)
	Arm 2: MMA embolization within 72h of surgery (randomized)
	Arm 3: MMA embolization only (not part of the randomization)
	Arm 4: No treatment (not part of the randomization)
Key inclusion and exclusion criteria	Inclusion criteria: age 18-100, consent possible, chronic subdural hematoma (cSDH) located at the convexities, patients with symptomatic cSDH, patients with asymptomatic large chronic/subacute hematoma after 6 weeks of failed conservative treatment
	Exclusion criteria: consent not possible, pregnancy, prisoner, angiography contraindication, patient for whom follow-up is problematic (e.g. distant residency, homeless…), previous surgery for cSDH
Study type	Interventional
	Allocation: randomized (arms 1 & 2), non-randomized (arms 3 & 4)
	Purpose: prevention of cSDH recurrence
	Phase: not applicable
Date of first enrolment	1st August, 2024
Target sample size	180
Recruitment status	Pending
Primary outcome(s)	cSDH recurrence, defined as a cSDH reappearance that requires surgical reoperation, a neurological deterioration due to a cSDH

	after evacuation, or a postoperative hematoma volume of more than 90% of the preoperative volume at follow-up (time frame: 6 weeks and 6 months)
Key secondary outcomes	Efficacy of MMA Embolization in Isolation for Stopping cSDH Progression Method of measurement: hematoma "regression", "stability" and "progression" are defined radiologically as >10% reduction in volume, +/-10% of previous volume, >10% increase in hematoma volume (time frame: 6 weeks and 6 months)
Ethics Review	Approved (16th January 2024) by Geneva and Ticino Ethics Commission for Research [ccer@eta.ge.ch; dss-ce@ti.ch]